Compare Citius Pharmaceuticals Inc (CTXR) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Xylem, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 1748.2× Citius Pharmaceuticals Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Xylem, Inc. for 50 Days on average.
| CTXR | XYL | |
|---|---|---|
Market Cap | $13.62M | $23.81B |
Volume | 132,438 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $1.82 | $152.95 |
52-Week Low | $0.48 | $100.92 |
Typical Hold Time | 17 Days | 50 Days |
Enterprise Value | $3.79M | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
XYL trades at $101.99, up 0.16% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 27, 2026. Revenue grew to $9.04B in 2025, and net income margin improved to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by solid fundamentals and a consensus price target of $149.13, implying significant upside. Risks include China market weakness and higher debt from recent note offerings. Analyst sentiment is mixed with 47.5% buy ratings, but institutional interest remains strong, as seen in Bank of America's new position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
